Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Alcohol Clin Exp Res. 2011 Jun 1;35(11):2030–2038. doi: 10.1111/j.1530-0277.2011.01554.x

Figure 2.

Figure 2

Percent days abstinent during the 6-week treatment trial for participants treated with flumazenil and gabapentin (A: FMZ/GBP) and with placebos (B: PLA). Participants who were treated with active medications who had greater than average improvement on the Stroop interference trial between Days 3 and 7 had more abstinence throughout the trial, while the opposite was true for participants treated with placebos. Figures are least-squares means (± standard errors) from the linear mixed model.